{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:59:11Z","timestamp":1780901951364,"version":"3.54.1"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hyperprolactinemia is a common endocrine disorder with significant reproductive and systemic implications. This study aimed to investigate the nationwide epidemiological trends, longitudinal shifts in pharmacological treatment, and the temporal associations of concurrent conditions and long-term sequelae in Korean women with claims-based hyperprolactinemia. Methods: A nationwide, population-based retrospective cohort study was conducted using data from the Health Insurance Review &amp; Assessment Service (HIRA) of South Korea from 2009 to 2021. Female patients aged 10\u201359 years with hyperprolactinemia diagnostic claims were evaluated. We analyzed annual prevalence, incidence, diagnostic procedures, and dopamine agonist prescription patterns. Associated clinical conditions were classified into two categories based on the timing of their diagnosis relative to hyperprolactinemia: concurrent or underlying conditions present at baseline, and long-term complications that developed during the follow-up period. Results: A total of 95,616 female patients were identified after applying the selection criteria. The prevalence and incidence of hyperprolactinemia peaked among women in their early thirties, with an absolute peak at age 32. A significant pharmacological paradigm shift was observed: bromocriptine was the predominant therapy during the early study period, but cabergoline prescriptions surpassed bromocriptine in 2017. Regarding clinical work-ups, only 5.3% of the entire cohort underwent a sella magnetic resonance imaging (MRI). Regarding associated clinical conditions, reproductive disorders such as infertility (28.0%) and polycystic ovary syndrome (24.8%) showed high overall prevalence but low incidence of new diagnoses during the follow-up period. Conversely, among the patients affected by bone disorders, more than 60% of the total osteoporosis and osteopenia cases were diagnosed subsequent to the initial hyperprolactinemia diagnosis. Significant post-diagnosis incidence was also observed for metabolic disorders, including dyslipidemia and diabetes mellitus. Conclusions: Hyperprolactinemia in Korean women is highly concentrated in the peak reproductive years. The shift toward cabergoline reflects evolving clinical guidelines and improved drug accessibility. Our findings highlight that while reproductive issues often present concurrently, bone loss and metabolic complications frequently emerge as post-diagnosis sequelae. Therefore, clinical management should extend beyond prolactin normalization to include proactive, multidisciplinary screening for skeletal and metabolic health.<\/jats:p>","DOI":"10.3390\/jcm15124411","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"4411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, Treatment Patterns, and Associated Clinical Conditions of Hyperprolactinemia Identified via Nationwide Claims Data in Korea: A 13-Year Population-Based Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-0888","authenticated-orcid":false,"given":"Hyonjee","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Eunpyeong St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-0847","authenticated-orcid":false,"given":"Kyung-Hee","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunkyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Uijeongbu St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngseo","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Eunpyeong St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaewon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Eunpyeong St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukil","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Namkung","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Eunpyeong St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11102-008-0107-5","article-title":"Hyperprolactinemia","volume":"11","author":"Chahal","year":"2008","journal-title":"Pituitary"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","article-title":"Hyperprolactinemia: Pathophysiology and therapeutic approach","volume":"31","author":"Capozzi","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin\u2014A pleiotropic factor in health and disease","volume":"15","author":"Bernard","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor Endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1507\/endocrj.K10E-215","article-title":"The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism","volume":"57","author":"Hekimsoy","year":"2010","journal-title":"Endocr. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hdi.12489","article-title":"Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis","volume":"21","author":"Lo","year":"2017","journal-title":"Hemodial. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1179558119871921","DOI":"10.1177\/1179558119871921","article-title":"PCOS and Hyperprolactinemia: What do we know in 2019?","volume":"13","author":"Delcour","year":"2019","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e-FPS04","DOI":"10.61622\/rbgo\/2024FPS04","article-title":"Hyperprolactinemia in women: Diagnostic approach","volume":"46","author":"Glezer","year":"2024","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12961","DOI":"10.1111\/eci.12961","article-title":"The value of prolactin in predicting prolactin\u03bfma in hyperprolactinaemic polycystic ovarian syndrome","volume":"48","author":"Kyritsi","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40290-023-00462-2","article-title":"Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review","volume":"37","author":"Junqueira","year":"2023","journal-title":"Pharm. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: A systematic review and meta-analysis","volume":"1","author":"Wang","year":"2012","journal-title":"Syst. Rev."},{"key":"ref_16","first-page":"Cd008605","article-title":"Dopamine agonists for preventing ovarian hyperstimulation syndrome","volume":"11","author":"Tang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yang, H., Lin, J., Li, H., Liu, Z., Chen, X., and Chen, Q. (2021). Prolactin Is Associated with Insulin Resistance and Beta-Cell Dysfunction in Infertile Women with Polycystic Ovary Syndrome. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.571229"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.gyobfe.2010.11.002","article-title":"Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: Myth or reality?","volume":"39","author":"Robin","year":"2011","journal-title":"Gynecol. Obstet. Fertil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1210\/js.2017-00328","article-title":"Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women with Chronic Amenorrhea","volume":"1","author":"Millar","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e3515","DOI":"10.1210\/clinem\/dgac166","article-title":"Kisspeptin Overcomes GnRH Neuronal Suppression Secondary to Hyperprolactinemia in Humans","volume":"107","author":"Hoskova","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1507\/endocrj.K06-026","article-title":"Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes","volume":"53","author":"Okamoto","year":"2006","journal-title":"Endocr. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2005.04.026","article-title":"Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue","volume":"331","author":"Nilsson","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12888","DOI":"10.1111\/jne.12888","article-title":"Metabolic functions of prolactin: Physiological and pathological aspects","volume":"32","author":"Brie","year":"2020","journal-title":"J. Neuroendocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","article-title":"The effects of hyperprolactinemia on bone and fat","volume":"12","author":"Schlechte","year":"2009","journal-title":"Pituitary"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: A clinical review","volume":"55","author":"Ajmal","year":"2014","journal-title":"Psychosomatics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","journal-title":"Endocrine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.maturitas.2021.06.014","article-title":"Hyperprolactinemia after menopause: Diagnosis and management","volume":"151","author":"Auriemma","year":"2021","journal-title":"Maturitas"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kim, M., Chae, K.H., Chung, Y.J., Hwang, H., Lee, M., Kim, H.K., Cho, H.H., Kim, M.R., Jung, C.Y., and Kim, S. (2020). The effect of the look-back period for estimating incidence using administrative data. BMC Health Serv. Res., 20.","DOI":"10.1186\/s12913-020-5016-y"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001\u20132011","volume":"171","author":"Gunnarsson","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: Structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Samperi, I., Lithgow, K., and Karavitaki, N. (2019). Hyperprolactinaemia. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122203"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3346\/jkms.2026.41.e103","article-title":"Integrated Clinical and Social Impacts of the COVID-19 Pandemic in Korea: A Combined Systematic and Narrative Review","volume":"41","author":"Jang","year":"2026","journal-title":"J. Korean Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cen.13156","article-title":"The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: The Prolactin Epidemiology, Audit and Research Study (PROLEARS)","volume":"86","author":"Newey","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3346\/jkms.2024.39.e85","article-title":"Risk Factors for Infertility in Korean Women","volume":"39","author":"Lee","year":"2024","journal-title":"J. Korean Med. Sci."},{"key":"ref_37","unstructured":"World Health Organization (2023). Infertility Prevalence Estimates, 1990\u20132021, World Health Organization."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3349\/ymj.2022.63.8.794","article-title":"Age-Adjusted Prevalence and Characteristics of Women with Polycystic Ovarian Syndrome in Korea: A Nationwide Population-Based Study (2010\u20132019)","volume":"63","author":"Kim","year":"2022","journal-title":"Yonsei Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"189","author":"Teede","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"Majumdar","year":"2013","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_41","first-page":"100412","article-title":"Mild hyperprolactinemia in women with polycystic ovary syndrome. Insights from a large cross-sectional study","volume":"41","author":"Insenser","year":"2025","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11102-007-0064-4","article-title":"Bone density in women with prolactinoma treated with dopamine agonists","volume":"11","author":"Naliato","year":"2008","journal-title":"Pituitary"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1590\/S0004-27302007000900016","article-title":"Decreased bone mineral density in pre-menopause women with prolactinoma","volume":"51","author":"Bussade","year":"2007","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ghobrial, S., Krysiak, R., Goldstein, T., Patsch, A., Paternostro, C., Heinzl, F., Marculescu, R., and Ott, J. (2025). Distribution of prolactin and its correlation with insulin resistance in women with polycystic ovary syndrome. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1674795"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kirsch, P., Kunadia, J., Shah, S., and Agrawal, N. (2022). Metabolic effects of prolactin and the role of dopamine agonists: A review. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1002320"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:21:43Z","timestamp":1780899703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124411"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124411","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]}}}